Oxford Textbook of Osteoarthritis and Crystal Arthropathy, Third Edition

Front Cover
Michael Doherty, Hans Bijlsma, Nigel Arden, Nicola Dalbeth, David Hunter
Oxford University Press, Oct 6, 2016 - Medical - 544 pages
A trustworthy clinical companion, the textbook offers best practice and management strategies for these common joint diseases.

Formerly published as Osteoarthritis, the extensively revised third edition of the Oxford Textbook of Osteoarthritis and Crystal Arthropathy provides up-to-date and evidence-based guidance on how to assess, diagnose, and manage patients. A prestigious and international author team ensure information is expert and relevant-this is a practical tool for clinicians managing people with osteoarthritis, gout, and other crystal-associated arthritis.

Confidently consider and chose the right blend of treatment for your patient, whether physical, pharmacological, surgical, or supportive. The Oxford Textbook of Osteoarthritis and Crystal Arthropathy provides full coverage of joint failure, and includes detailed sections on epidemiology, risk factors, clinical assessment, and investigations. This edition also now includes new sections on gout and other crystal arthropathies.

Clinically relevant and easily understandable overviews of basic science, including pathology and pain physiology, along with critical appraisal of current guidelines, make this a highly valuable resource. Significant coverage is also given to patient education and the involvement of the patient in management planning.

Also highly illustrated, the textbook is a strong reference tool with summary boxes and key points at the end of chapters making it easy to find information quickly and help you deliver the optimum patient outcome. The textbook equips rheumatologists and musculoskeletal health professionals with the knowledge to provide best possible patient care.

 

What people are saying - Write a review

We haven't found any reviews in the usual places.

Contents

Section 2 Tissues
31
Section 3 Epidemiology
79
Section 4 Risk factors
91
Section 5 Pain
123
Section 6 Clinical assessment
139
Section 7 Management
201
Section 8 Pharmacological therapies
277
Section 9 Surgery
323
Section 10 Prospects for disease modification
341
Section 11 Delivery of care
353
Section 12 Guidelines
369
Section 13 Gout
381
Section 14 Calcium pyrophosphate crystal deposition
459
Section 15 Basic calcium phosphate crystal deposition
487
Index
499
Copyright

Other editions - View all

Common terms and phrases

About the author (2016)


Michael Doherty, Head of Department and Director of Clinical & Epidemiological Research, Faculty of Medicine and Health Sciences, University of Nottingham, UK, Hans Bijlsma, Professor of Rheumatology, University of Amsterdam and Free University at Amsterdam, The Netherlands, Nigel Arden, Professor in Rheumatic Diseases, Director of Musculoskeletal Epidemiology and Biobank, University of Oxford, UK, David Hunter, Florance and Cope Chair of Rheumatology Medicine, Royal North Shore Hospital, The University of Sydney, Australia, Nicola Dalbeth, Associate Professor, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand

Professor Michael Doherty MA MD FRCP FHEA is Professor of Rheumatology and Head of Division of Rheumatology, Orthopaedics and Dermatology, School of Medicine, University of Nottingham. His main research interests are osteoarthritis (OA), gout, calcium pyrophosphate crystal deposition (CPPD), placebo/contextual response and evidence based medicine. He has expertise in clinical and epidemiological studies, community-based clinical trials, systematic reviews and meta-analyses. He has over 300 original research publications and was awarded the OA Research Society International (OARSI) Clinical Research Award for 2012. He is a past editor of Annals of the Rheumatic Diseases (1992-99), has co-chaired EULAR Task Forces for recommendations for OA, gout and CPPD arthritis, and has been involved as a clinical expert in NICE appraisals for OA and gout.

Johannes (Hans) Bijlsma is professor of Rheumatology at the University of Utrecht, as well as at both Universities (VU and UVA) in Amsterdam. He was Head of the Department of Rheumatology and Immunology in Utrecht (1989-2013) and of the Amsterdam Rheumatology and immunology Center (2013-2015).
His main research interests are osteoarthritis (OA), treatment strategies in rheumatoid arthritis and glucocorticoids. He has expertise in clinical and epidemiological studies, randomised controlled clinical trials in early RA, systematic reviews and meta-analyses. He has over 600 original research publications and was awarded the Jan van Breemen Award for his scientific work in the Netherlands (2015). He is an associate editor of Annals of the Rheumatic Diseases (2005 - ongoing), has co-chaired EULAR Task Forces for recommendations for OA and the use of glucocorticoids. He has been the chair of Education of EULAR, the coordinator of the EULAR online courses and is presently the President-elect of EULAR

Nigel Arden is a Professor of Rheumatic Diseases and an International Leader in Epidemiology and predictive modelling and trial design. He has clinical and research expertise in osteoarthritis, arthroplasty and osteoporosis and has published numerous manuscripts based on the use of cohort and large routinely collected databases in musculoskeletal diseases and their treatment. His research interests focus on the epidemiology of musculoskeletal diseases, with a focus on Osteoarthritis and Osteoporosis. He is based in the Botnar Research Centre, University of Oxford with additional sessions at the MRC Lifecourse Epidemiology Unit at the University of Southampton.

Professor David Hunter is a rheumatology clinician researcher whose main research focus has been clinical and translational research in osteoarthritis (OA). He is the Florance and Cope Chair of Rheumatology and Professor of Medicine at University of Sydney, and Staff Specialist at Royal North Shore Hospital and North Sydney Orthopaedic and Sports Medicine Centre. His research is focused on a number of key elements in OA including (but not limited to) the epidemiology of osteoarthritis, the application of imaging to better understand structure and function with application to both epidemiologic research and clinical trials, novel therapies in disease management and heath service system delivery of chronic disease management. He is an editor for leading international journals in his field. He has authored books on osteoarthritis and has over 350 publications in peer reviewed journals.

Professor Nicola Dalbeth is an academic rheumatologist who leads a clinical and laboratory programme of research in gout, an inflammatory arthritis of major significance to Aotearoa New Zealand. Her work focuses on understanding the impact and mechanisms of disease in gout. She is a founding member of the Counties Manukau District Health Board Maori Gout Action Group, and she was the Lead Clinical Advisor for the Gout Clinical Pathways (Greater Auckland Integrated Healthcare Network) and the national bpac Gout Treatment Guidelines. She has served as an Expert Panel member on the American College of Rheumatology Gout Management Guidelines, and is a steering committee member for the OMERACT gout working group and the ACR/EULAR gout classification project.

Bibliographic information